Raloxifene

• CAT Number: R044961
• CAS Number: 84449-90-1
• Molecular Formula: C28H27NO4S
• Molecular Weight: 473.587
• Purity: ≥95%
• Storage: Desiccate at RT
• IUPAC Name: [6-hydroxy-2-(4-hydroxyphenyl)-1-benzothiophen-3-yl]-[4-(2-piperidin-1-ylethoxy)phenyl]methanone
• InChI: InChI=1S/C28H27NO4S/c30-21-8-4-20(5-9-21)28-26(24-13-10-22(31)18-25(24)34-28)27(32)19-6-11-23(12-7-19)33-17-16-29-14-2-1-3-15-29/h4-13,18,30-31H,1-3,14-17H2
• InChIKey: GZUITABIAKMVPG-UHFFFAOYSA-N
• SMILES: C1CCN(CC1)CCOC2=CC=C(C=C2)C(=O)C3=C(SC4=C3C=CC(=C4)O)C5=CC=C(C=C5)O

Raloxifene (Cat No.:R044961), also known as Keoxifene; LY 139481; [2-(4-Hydroxyphenyl)-6-hydroxybenzo[b]thien-3-yl][4-(2-(1-piperidinyl)ethoxy)phenyl]methanone; Raloxifenine, etc. Raloxifen has estrogen agonistic effect in bone and cardiovascular system, and estrogen antagonistic effect in uterus and breast. It can be used to prevent and treat osteoporosis in postmenopausal women, improve menopausal symptoms of postmenopausal women, and has potential cardiovascular protection.

Reference

1:Erratum to: Raloxifene Administration in Women Treated with Long Term Gonadotropin-releasing Hormone Agonist for Severe Endometriosis: Effects on Bone Mineral Density. Cho YH, Um MJ, Kim SJ, Kim SA, Jung H.J Menopausal Med. 2017 Apr;23(1):77. doi: 10.6118/jmm.2017.23.1.77. Epub 2017 Apr 28. PMID: 28523264 2:Combination Therapy of Raloxifene and Alendronate for Treatment of Osteoporosis in Elderly Women. Um MJ, Cho EA, Jung H.J Menopausal Med. 2017 Apr;23(1):56-62. doi: 10.6118/jmm.2017.23.1.56. Epub 2017 Apr 28. PMID: 28523260 3:Effects of 17β-estradioland raloxifene on endothelial OPG and RANKL secretion. Karwowski W, Lekesiz K, Koc-Żórawska E, Wnuczko K, Borysewicz-Sanczyk H, Naumnik B.Ginekol Pol. 2017;88(4):167-173. doi: 10.5603/GP.a2017.0033. PMID: 28509316 Free Article4:Preparation, characterization and in vitro evaluation of microemulsion of raloxifene hydrochloride. Golmohammadzadeh S, Farhadian N, Biriaee A, Dehghani F, Khameneh B.Drug Dev Ind Pharm. 2017 May 19:1-7. doi: 10.1080/03639045.2017.1328430. [Epub ahead of print] PMID: 28489426 5:Growth-suppressive activity of raloxifene on liver cancer cells by targeting IL-6/GP130 signaling. Wang Y, Ma H, Zhao C, Liu T, Yan D, Jou D, Li H, Zhang C, Lü J, Li C, Lin J, Li S, Lin L.Oncotarget. 2017 May 16;8(20):33683-33693. doi: 10.18632/oncotarget.16898. PMID: 28430601 Free Article6:Raloxifene but not alendronate can compensate the impaired osseointegration in osteoporotic rats. Faverani LP, Polo TO, Ramalho-Ferreira G, Momesso GA, Hassumi JS, Rossi AC, Freire AR, Prado FB, Luvizuto ER, Gruber R, Okamoto R.Clin Oral Investig. 2017 Mar 29. doi: 10.1007/s00784-017-2106-2. [Epub ahead of print] PMID: 28357643 7:Involvement of HSP70 and HO-1 in the protective effects of raloxifene on multiple organ dysfunction syndrome by endotoxemia in ovariectomized rats. Shen HH, Huang SY, Cheng PY, Chu YJ, Chen SY, Lam KK, Lee YM.Menopause. 2017 Mar 27. doi: 10.1097/GME.0000000000000864. [Epub ahead of print] PMID: 28350760 8:Effect of osteoporosis medication on changes in bone mineral density and bone turnover markers after 24-month administration of daily teriparatide: comparison among minodronate, raloxifene, and eldecalcitol. Nakatoh S.J Bone Miner Metab. 2017 Mar 14. doi: 10.1007/s00774-017-0829-4. [Epub ahead of print] PMID: 28293779 9:Raloxifene Lowers Plasma Lipoprotein(a) Concentrations: a Systematic Review and Meta-analysis of Randomized Placebo-Controlled Trials. Ferretti G, Bacchetti T, Simental-Mendía LE, Reiner Ž, Banach M, Sahebkar A.Cardiovasc Drugs Ther. 2017 Apr;31(2):197-208. doi: 10.1007/s10557-017-6721-6. PMID: 28265881 10:Induction of mitochondrial apoptotic pathway by raloxifene and estrogen in human endometrial stromal ThESC cell line. Nikolic I, Andjelkovic M, Zaric M, Zelen I, Canovic P, Milosavljevic Z, Mitrovic M.Arch Med Sci. 2017 Mar 1;13(2):293-301. doi: 10.5114/aoms.2016.59874. Epub 2016 May 12. PMID: 28261281 Free PMC Article